Lilly Announces U.S. Availability Of Trulicity

(RTTNews) - Eli Lilly and Co. (LLY) said Monday that Trulicity, a once-weekly, glucagon-like peptide-1 receptor agonist injectable prescription medicine indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, is now available in U.S. pharmacies.

Trulicity comes in a single-dose pen and does not require the patient to mix, measure, or handle the needle.

Trulicity has a Boxed Warning about potential risk of thyroid c-cell tumors including medullary thyroid carcinoma. It is contraindicated in patients with a personal history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 and in patients with a prior serious hypersensitivity reaction to dulaglutide or any of its product components.

The U.S. Food and Drug Administration approved Trulicity on September 18 based on results from a number of studies of Trulicity used alone or in combination with commonly prescribed diabetes medications, including metformin, pioglitazone, glimepiride, and insulin lispro. It is now available to patients in 0.75 mg and 1.5 mg doses, delivered in the single-dose Trulicity pen. In a separate usability study, most patients agreed the Trulicity pen was easy to use.